<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               8 USE IN SPECIFIC POPULATIONS<BR><BR>               <BR>               <BR>                  <BR>                     <BR>                        G6PD Deficiency (8.6).<BR><BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     8.1 Pregnancy<BR><BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 Teratogenic Effects: Pregnancy Category C<BR>                              <BR>                              There are no adequate and well controlled studies in pregnant women. Dapsone has been shown to have an embryocidal effect in rats and rabbits when administered orally in doses of 75 mg/kg/day and 150 mg/kg/day (approximately 800 and 500 times the systemic exposure observed in human females as a result of use of the maximum recommended topical dose, based on AUC comparisons), respectively. These effects were probably secondary to maternal toxicity. ACZONE<BR>                                 ® Gel, 5%, should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.<BR><BR>                           <BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     8.3 Nursing Mothers<BR><BR>                     <BR>                        Although systemic absorption of dapsone following topical application of ACZONE<BR>                           ® Gel, 5%, is minimal relative to oral dapsone administration, it is known that dapsone is excreted in human milk. Because of the potential for oral dapsone to cause adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue ACZONE<BR>                           ® Gel, 5%, taking into account the importance of the drug to the mother.<BR><BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     8.4 Pediatric Use<BR><BR>                     <BR>                        Safety and efficacy was evaluated in 1169 children aged 12-17 years old treated with ACZONE<BR>                           ® Gel, 5%, in the clinical studies. The adverse event rate for ACZONE<BR>                           ® Gel, 5%, was similar to the vehicle control group. Safety and efficacy was not studied in pediatric patients less than 12 years of age, therefore ACZONE<BR>                           ® Gel, 5%, is not recommended for use in this age group.<BR><BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     8.5 Geriatric Use<BR><BR>                     <BR>                        Clinical studies of ACZONE<BR>                           ® Gel, 5%, did not include sufficient number of patients aged 65 and over to determine whether they respond differently from younger patients.<BR><BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     8.6 G6PD Deficiency<BR><BR>                     <BR>                        <BR>                           ACZONE<BR>                           ® Gel, 5% and vehicle were evaluated in a randomized, double-blind, cross-over design clinical study of 64 patients with G6PD deficiency and acne vulgaris. Subjects were Black (88%), Asian (6%), Hispanic (2%) or of other racial origin (5%). Blood samples were taken at Baseline, Week 2, and Week 12 during both vehicle and ACZONE<BR>                           ® Gel, 5% treatment periods. There were 56 out of 64 subjects who had a Week 2 blood draw and applied at least 50% of treatment applications. Table 3 contains results from testing of relevant hematology parameters for these two treatment periods. ACZONE<BR>                           ® Gel was associated with a 0.32 g/dL drop in hemoglobin after two weeks of treatment, but hemoglobin levels generally returned to baseline levels at Week 12.<BR><BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:voc="urn:hl7-org:v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="t3" width="100%"><BR>                           <caption>Table 3 &#8211; Mean Hemoglobin, Bilirubin, and Reticulocyte Levels in Acne Subjects with G6PD Deficiency in ACZONE<sup>&#174;</sup>/Vehicle Cross-Over Study<BR></caption><BR>                           <col width="29.417%" align="left"/><BR>                           <col width="22.650%" align="left"/><BR>                           <col width="11.983%" align="left"/><BR>                           <col width="13.317%" align="left"/><BR>                           <col width="9.317%" align="left"/><BR>                           <col width="13.317%" align="left"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td colspan="2" rowspan="2" align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/><BR>                                 <td colspan="2" align="left" valign="top" styleCode="Toprule Botrule Rrule"><BR>                                    <content styleCode="bold">ACZONE</content><BR>                                    <sup>&#174;</sup><BR>                                 </td><BR>                                 <td colspan="2" align="left" valign="top" styleCode="Toprule Botrule Rrule"><BR>                                    <content styleCode="bold">Vehicle</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">N<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">Mean<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">N<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">Mean<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td rowspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">Hemoglobin (g/dL)<BR></td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">Pre-treatment<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">53<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">13.44<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">56<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">13.36<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">2 weeks<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">53<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">13.12<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">55<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">13.34<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">12 weeks<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">50<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">13.42<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">50<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">13.37<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td rowspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">Bilirubin (mg/dL)<BR></td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">Pre-treatment<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">54<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0.58<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">56<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0.55<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">2 weeks<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">53<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0.65<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">55<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0.56<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">12 weeks<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">50<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0.61<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">50<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">0.62<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td rowspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">Reticulocytes (%)<BR></td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">Pre-treatment<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">53<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1.30<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">55<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1.34<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">2 weeks<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">53<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1.51<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">55<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1.34<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">12 weeks<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">50<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1.48<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">50<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1.41<BR></td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>There were no changes from baseline in haptoglobin or lactate dehydrogenase during ACZONE<BR>                           ® or vehicle treatment at either the 2-week or 12-week time point.<BR><BR>                        The proportion of subjects who experienced decreases in hemoglobin ≥1 g/dL was similar between ACZONE<BR>                           ® Gel, 5% and vehicle treatment (8 of 58 subjects had such decreases during ACZONE<BR>                           ® treatment compared to 7 of 56 subjects during vehicle treatment among subjects with at least one on-treatment hemoglobin assessment). Subgroups based on gender, race, or G6PD enzyme activity did not display any differences in laboratory results from the overall study group. There was no evidence of clinically significant hemolytic anemia in this study. Some of these subjects developed laboratory changes suggestive of mild hemolysis.<BR><BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>